CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (402,826)	$ (269,250)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	4,077	1,404
Changes in assets and liabilities:
Prepaid expenses and other receivables	9,085	(44,015)
Accounts payable and other liabilities	35,064	106,781
Prepayment to related party for clinical trials	177,794	(561,132)
Net cash used in operating activities	(176,806)	(766,212)
Cash Flows from Investing Activities:
Increase in restricted cash	0	(9,455)
Purchase of intangible assets	(48,611)	(1,373)
Purchase of property and equipment	(4,767)	0
Net Cash used in investing activities	(53,378)	(10,828)
Cash Flows From Financing Activities:
Net cash provided by financing activities	0	0
Net decrease in cash	(230,184)	(777,040)
Effect of exchange rate changes on cash	1,266	15,593
Cash at beginning of period	354,749	1,873,141
Cash at end of period	$ 125,831	$ 1,111,694